Epigenetic Silencing of Immune-Checkpoint Receptors in Bone Marrow- Infiltrating T Cells in Acute Myeloid Leukemia.

ABSTRACT:

Background

Immune-checkpoint (IC) inhibitors have revolutionized the treatment of multiple solid tumors and defined lymphomas, but they are largely ineffective in acute myeloid leukemia (AML). The reason why especially PD1/PD-L1 blocking agents are not efficacious is not well-understood but it may be due to the contribution of different IC ligand/receptor interactions that determine the function of T cells in AML.

Methods

To analyze the interactions of IC ligands and receptors in AML, we performed a comprehensive transcriptomic analysis of FACS-purified leukemia stem/progenitor cells and paired bone marrow (BM)-infiltrating CD4⁺ and CD8⁺ T cells from 30 patients with AML. The gene expression profiles of activating and inhibiting IC ligands and receptors

SUBMITTER: Radpour R 

PROVIDER: S-EPMC8130556 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature